PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 17.5% in January

PAVmed Inc. (NASDAQ:PAVM) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 357,100 shares, a decrease of 17.5% from the December 31st total of 432,900 shares. Based on an average daily volume of 153,700 shares, the days-to-cover ratio is presently 2.3 days. Approximately 3.7% of the shares of the company are short sold.

PAVmed Stock Performance

NASDAQ PAVM traded down $0.00 on Monday, reaching $0.66. 206,183 shares of the company’s stock traded hands, compared to its average volume of 204,190. PAVmed has a fifty-two week low of $0.57 and a fifty-two week high of $3.50. The firm has a market cap of $7.31 million, a price-to-earnings ratio of -0.15 and a beta of 0.73. The stock has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.95.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their target price on PAVmed from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.